About Us
Company Profile
Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (stock code: 02179.HK) is an innovative vaccine company propelled by internally developed technologies. Committed to our mission of " Protect human health with best-in-class vaccines", we have developed a comprehensive vaccine innovation engine consisting of a novel adjuvant platform, protein engineering platform and immunological evaluation platform. We are one of the few companies that are capable of independently developing and commercializing a full range of novel adjuvants. Our vaccine portfolio currently consists of more than 10 high-value innovative vaccine pipelines, covering HPV, shingles, RSV and other major diseases. Our core products recombinant HPV 9-valent vaccine REC603 and novel adjuvanted recombinant shingles vaccine REC 610, are under phase III clinical trial.
Leadership
non-executive Director、Chairman of the Board
non-executive Director、Chairman of the Board
Mr. XU Haoyu is currently a representative of the 14th National People’s Congress, president of the Medical and Pharmaceutical Chamber of Commerce of China Federation of Industry and Commerce, and secretary of the Party Committee, chairman and president of Yangtze River Pharmaceutical (Group) Co., Ltd.and a Chairman of Recbio.
Mr. XU Haoyu actively supports the “Healthy China” strategy and is dedicated to building a world-class pharmaceutical and health enterprise. He has driven the establishment of a global quality management system, leading Yangtze River Pharmaceutical Group to win the prestigious EFQM Global Award (Seven-Star), one of the world’s top three quality awards. Adhering to the philosophy of “strengthening the enterprise through technology,” he has solidified the company’s foundation in the pharmaceutical sector while expanding into new dimensions to build a new ecosystem for the big health industry.Under his leadership, the group’s companies have consistently ranked among the top pharmaceutical manufacturers in the China Top 500 Private Enterprises for many years. With products exported to over 40 countries and regions, he has made significant contributions to the high-quality development of China’s national pharmaceutical industry and the advancement of public health. Actively fulfilling his duties, Mr. Xu has proposed key initiatives during the national “Two Sessions,” including promoting the big health industry and advancing the modernization of Traditional Chinese Medicine (TCM). In July 2025, Mr. XU Haoyu was named one of the 6th “Outstanding Builders of Socialism with Chinese Characteristics” from the non-public sector.
Founder, Executive Director and CEO
Founder, Executive Director and CEO
Dr. Liu Yong is responsible for the overall management of Recbio business strategy, corporate development and R&D.
Dr. Liu holds a Ph.D. in Pathogenic Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College, and a Bachelor's degree in Microbial Engineering from Shandong University. Dr. Liu has 30 years of experience in innovative vaccine R&D and industrialization. Before founding Recbio, he worked at the National Center for STD and AIDS Prevention and Control of the Chinese Center for Disease Control and Prevention for 10 years, serving as an associate researcher and researcher. During this period, he served as a visiting researcher at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH) and the University of Maryland. He is currently the Executive Director and CEO of Jiangsu Recbio Technology Co., Ltd., a member of the People's Congress of Taizhou City, Jiangsu Province, an executive director of the Jiangsu Association for the Promotion of Foreign Friendship and Exchanges, a director of the Jiangsu International Cultural Exchange Center, and the Vice President of the Pharmaceutical Industry Branch of the Shandong University Alumni Association.
Executive Director, Chief Quality Officer
Executive Director, Chief Quality Officer
Ms. Wang Jing is responsible for quality management, regulatory affairs, and public affairs at Recbio.
She holds a Master’s degree in Biomedical Engineering from Sichuan University and is a Professor-level Senior Engineer. Previously, she served at the Chengdu Institute of Biological Products under the China National Biotec Group (CNBG). Ms. Wang possesses over 20 years of experience in vaccine R&D, commercial production, and quality management. She is well-versed in both international and domestic pharmaceutical regulations and has successfully organized and led numerous WHO PQ (Prequalification) on-site inspections and re-inspections. With extensive experience in vaccine registration and a track record of successful filings, she also maintains strong public relations. Furthermore, she specializes in the establishment and maintenance of GMP quality management systems that integrate ISO standards for quality, environment, and occupational health and safety.
Executive Director, Assistant to the Chairman, and Board Secretary
Executive Director, Assistant to the Chairman, and Board Secretary
Mr. Wei Qifang is responsible for securities investment at Recbio.
Mr. Wei Qifang is a PhD candidate in Accounting at Wuhan University, holds an MBA from the University of Poitiers, France, and a Bachelor’s degree in Finance from Zhongnan University of Economics and Law. He has also obtained multiple professional qualifications, including Certified Public Accountant (CPA) in China, Chartered Financial Analyst (CFA), Sponsor Representative in China, and Chinese legal professional qualification. Mr. Wei has over 30 years of extensive experience in corporate management, investment banking, capital operations, and financial strategy. Prior to joining Recbio, he served as the Chief Financial Officer and Chief Information Officer (CFO/CIO) of Yangtze River Pharmaceutical Group Co., Ltd. and has also held positions at ZTE Corporation and Guosen Securities.
Chief Operating Officer
Chief Operating Officer
Mr. Zhou Yang is responsible for the production, engineering, storage and transportation of Recbio. Mr. Zhou Yang holds a bachelor's degree in biotechnology from East China Normal University in Shanghai. Before joining Recbio, he served as deputy general manager of Sinopharm Chengdu Institute of Biological Products Co., Ltd. He has more than 20 years of experience in the vaccine industry and has rich professional and management experience in quality management, pharmacovigilance, storage and transportation, safety and environmental protection and other business areas.
The finance director
The finance director
Mr. Zhou Lei is responsible for the financial management and auditing of Recbio.
Mr. Zhou Lei holds a bachelor's degree in accounting from Jiangsu University of Science and Technology, and has obtained qualification certificates such as intermediate accountant, senior accountant, and certified tax accountant. Mr. Zhou has registered as a Chinese certified public accountant with the Chinese Institute of Certified Public Accountants. Mr. Zhou Lei has extensive professional experience in financial management and tax management of pharmaceutical companies. Before joining Recbio, he worked at Yangtze River Pharmaceutical Group Co., Ltd. as the financial director.
Chief Science Officer
Chief Science Officer
Dr. Hong Kunxue is responsible for providing guidance and advice on R&D strategies of Recbio.
Dr. Hong holds a PhD in Genetics from Union Medical College, China, a Master's Degree in Clinical Laboratory Diagnostics from Jilin Medical College, China (now known as Beihua University), and a Bachelor's Degree in Clinical Medicine from Henan Medical University, China (now known as Zhengzhou University). Completed relevant postdoctoral research at the Chinese Center for Disease Control and Prevention. Dr. Hong has served as a research scholar at the University of California, Los Angeles, a leading academic institution in the United States, and as a visiting scholar at the Human Vaccine Institute of Duke University. He has more than 30 years of experience in immunology research at the Chinese Center for Disease Control and Prevention. He has worked at the Chinese CDC Center for STD and AIDS Prevention and Control for nearly 13 years and serves as a member of the Academic Committee and Degree Committee. Dr. Hong serves on the editorial board of "Infectious Microorganisms and Diseases (English)". Dr. Hong Kunxue has published more than 100 articles in academic journals in immunology and other related fields. Dr. Hong was awarded a Certificate of Honor for Fighting COVID-19 by the Hubei Provincial People's Government in April 2020. Dr. Hong was appointed as Optics Valley Industry Professor by Wuhan University in December 2021.
Executive Director
Executive Director
Mr. Lan Yong is responsible for the marketing and strategic planning at Recbio.
Mr. Lan Yong is a PhD candidate in Public Health at Johns Hopkins University, and holds a Master of Public Health (MPH) from Heidelberg University, Germany, and a Master of Business Administration (MBA) from Peking University. He has over 18 years of experience in the pharmaceutical and public health sectors. Prior to joining Recbio, Mr. Lan Yong served at the Chinese Center for Disease Control and Prevention (China CDC) and held key management positions at multinational pharmaceutical companies such as Pfizer, Merck, and Sanofi Pasteur, as well as at Yangtze River Pharmaceutical Group, with responsibilities covering medical strategy, marketing, innovative market access, alliance management, and strategic planning.
Chief Human Resource Officer
Chief Human Resource Officer
Mr. Li Bu is responsible for the daily operation and strategic development of Recbio human resources, IT, administration and procurement business.
Mr. Li Bu holds a master's degree in business administration from Kunming University and a bachelor's degree in technical economics from Central South University of Technology. He has more than 21 years of experience in human resources management. Before joining Recbio, Mr. Li Bu worked in human resources at Kunming Pharmaceutical Group Co., Ltd., served as assistant to the general manager of Yunnan Watson Biotechnology Co., Ltd., served as human resources director at Yunnan Belle Shoes Co., Ltd., and served as general manager at Kunming Hanyu Business Consulting Co., Ltd.
Awards & Certificates
Milestones
Collaborations
